Raymond James initiated coverage of Monopar Therapeutics (MNPR) with a Strong Buy rating and $80 price target Even with the stock’s 60% rally in 2025, the market continues to discount the upside potential from the newly acquired ALXN1840 for Wilson disease, the analyst tells investors in a research note. The firm sees additional upside in the shares and recommends buying at current levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR: